Real-world outcomes with DPd vs DKd in RRMM

Results from a multicenter retrospective study, comparing real-world outcomes with daratumumab + pomalidomide + dexamethasone (DPd; n = 295) vs daratumumab + carfilzomib + dexamethasone (DKd; n = 104) for the treatment of patients with relapsed/refractory multiple myeloma (RRMM), were published in Clinical Lymphoma, Myeloma & Leukemia by Zayad et al. The primary outcome was progression-free survival (PFS).

Key data: Median PFS was 15 months (95% confidence interval [CI], 11–18) with DPd vs 12 months (95% CI, 8–17) with DKd (p = 0.2), while median overall survival (OS) was 38 months (95% CI, 34–57) and not reached, respectively (p = 0.5). DPd was associated with higher rates of Grade ≥3 neutropenia (36% vs 23%) and leukopenia (26% vs 14%), while DKd showed a greater incidence of cardiovascular adverse events (29% vs 18%).

Key learning: DPd and DKd demonstrated comparable real-world clinical efficacy in RRMM, with distinct toxicity profiles, supporting individualized regimen selection based on patient comorbidities, prior treatment exposure, and tolerance to hematologic or cardiovascular toxicity.